Why people use Semaglutide for women over 40
Perimenopausal weight gain. Wegovy / Ozempic? The honest answer: the signal shows up in subgroup data, so treat it as suggestive, not settled. Largest demographic on Wegovy by far.
This page covers what's known, what's not, and what the editorial take is for normal humans considering Semaglutide for women over 40.
What the evidence says
Evidence tier: Subgroup analysis. Trial subgroup data supports use in this population; broader trial design didn't target the subgroup.
- Largest demographic on Wegovy by far.
- Effective across the perimenopausal transition.
- Often paired with hormone therapy with no documented interaction issues.
Protocol notes
Standard dosing. Coordinate with PCP or gynecologist if on HT.
Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.
What to skip
- Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
- Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
- Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.
Where to go next
- Full Semaglutide directory entry - status, sourcing, studies, what to skip
- What are peptides - if you skipped the foundation
- How peptides actually work - mechanism in plain English
- The Tier List - which ones to take seriously
- Subscribe to the dispatch